Metabolic (GLP-1 / GIP)

The metabolic family is built on incretin receptor agonists, Semaglutide, Tirzepatide and Retatrutide, and on how single, dual and triple agonism is studied in metabolic research.

These are the most researched peptides in the modern catalogue. They imitate the body's own gut hormones, and the difference between compounds comes down to how many incretin receptors a single molecule engages.

The incretin system

Incretins are hormones released by the gut after eating. The two central ones are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together they help govern blood-sugar regulation and appetite signalling. An incretin agonist is a peptide engineered to activate those same receptors, which is why this family is studied so heavily in metabolic models.

Single, dual and triple agonists

The three in-stock compounds are distinguished by how many incretin pathways each one activates.

Availability: In stock for all three.

What the research looks at

Study models of this family focus on the downstream effects of activating incretin receptors. Commonly investigated in research and animal models are:

• Slowed gastric emptying, how quickly the stomach empties after a meal.
• Glucose-dependent insulin signalling, insulin release that scales with blood-sugar levels.
• Appetite drive, central pathways governing satiety, studied in research models.

Why half-life matters

Incretin agonists in this family are engineered for long half-lives, which is what allows once-weekly study designs rather than daily handling in research protocols. They are also highly potent, so accurate, reproducible concentration measurement is central to any research preparation, small differences in the maths matter. See the measurement guide before preparing a research solution.